替吉奥联合奥沙利铂治疗对中晚期胃癌患者血清胃泌素、survivin抗体表达的影响  

Effect of Tegafur, Gimeracil and Oteracil Porassium Capsules combined with Oxaliplatin on the expression of gastrin and survivin antibodies in serum of patients with advanced gastric cancer

作　　者：吕秀娟[1] 陈新[1] 王艳[1] LYU Xiujuan;CHEN Xin;WANG Yan(Department of Geriatric Oncology, the 4th People′s Hospital of Shenyang City, Liaoning Province, Shenyang 110031, China)

机构地区：[1]辽宁省沈阳市第四人民医院老年肿瘤科,辽宁沈阳110031

出　　处：《中国医药导报》2019年第11期97-100,共4页China Medical Herald

摘　　要：目的探讨替吉奥联合奥沙利铂治疗中晚期胃癌的临床效果及对患者血清胃泌素(GAS)、survivin抗体表达的影响。方法将2015年1月～2017年6月沈阳市第四人民医院收治的100例中晚期胃癌患者,依照随机信封法分为观察组及对照组,每组50例。对照组采用卡培他滨联合奥沙利铂治疗,观察组采用替吉奥联合奥沙利铂治疗。两组均冶疗4个周期。治疗结束后对短期临床疗效进行评估,对患者治疗出现的不良反应及生活质量进行评估。治疗前后检测患者血中GAS及survivin抗体水平。结果观察组短期治疗总有效率显著高于对照组(P <0.01),治疗后观察组患者生活质量总改善率显著高于对照组(P <0.01)。治疗后两组患者GAS及survivin抗体均较治疗前降低(P <0.05),治疗后观察组患者血清GAS及survivin抗体水平均明显低于对照组(P <0.01)。治疗后观察组腹泻、恶心呕吐发生率显著低于对照组(P <0.01)。结论采用替吉奥联合奥沙利铂治疗中晚期胃癌可有效提高临床疗效并降低患者血清GAS及survivin抗体水平,具有较高临床应用价值。Objective To investigate the clinical efficacy of Tegafur, Gimeracil and Oteracil Porassium Capsules combined with Oxaliplatin in the treatment of advanced gastric cancer and its effect on the expression of gastrin (GAS) and survivin antibodies in serum. Methods A total of 100 patients with advanced gastric cancer treated in the 4th People′s Hospital of Shenyang City from January 2015 to June 2017 were divided into observation group and control group by random envelope method, with 50 cases in each group. The control group was treated with Capecitabine combined with Oxaliplatin, and the observation group was treated with Tegafur, Gimeracil and Oteracil Porassium Capsules combined with Oxaliplatin. Both groups were treated for 4 cycles. After treatment, the short-term clinical efficacy was assessed, and adverse reactions and quality of life were evaluated. Blood GAS and survivin antibody levels were detected before and after treatment. Results The short-term total effective rate of treatment in the observation group was significantly higher than that in the control group(P < 0.05). The total improvement rate of the quality of life in the observation group after treatment was significantly higher than that of the control group (P < 0.05). GAS and survivin of patients in the two groups significantly decreased after treatment (P < 0.05). The GAS and survivin antibodies in the blood of the patients were significantly lower than those in the control group (P < 0.05), and the incidence of nausea, vomiting and diarrhea in the observation group was significantly lower than that of the control group (P < 0.05). Conclusion The combination of Tegafur, Gimeracil and Oteracil Porassium Capsules and Oxaliplatin can effectively improve the clinical efficacy and reduce the levels of serum GAS and survivin antibody in patients with advanced gastric cancer. It is of high clinical value.

关 键 词：替吉奥 奥沙利铂 中晚期胃癌 胃泌素 SURVIVIN抗体 

分 类 号：R735.2[医药卫生—肿瘤]